Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome

References

• Kinsbourne M. Myoclonic encephalopathy of infants. J. Neurol. Neurosurg. Psychiatr.25(2), 271–279 (1962).
   PubMed Web of Science ®Google Scholar
• Solomon G, Churtorian AM. Opsoclonus and occult neuroblastoma. New Engl. J. Med.279(9), 475–477 (1968).
   PubMed Web of Science ®Google Scholar
• Dyken P, Kolar O. Dancing eyes, dancing feet: infantile polymyoclonia. Brain91(2), 305–320 (1968).
   PubMed Web of Science ®Google Scholar
• Plantaz D, Michon J, Valteau-Couanet D et al. [Opsoclonus–myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists]. Arch. Pediatr.7(6), 621–628 (2000).
   PubMed Web of Science ®Google Scholar
• Mitchell WG, Davalos-Gonzalez Y, Brumm VL et al. Opsoclonus–ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics109(1), 86–98 (2002).
   PubMedGoogle Scholar
• Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus–myoclonus syndrome. J. Pediatr. Oncol. Nurs.22(1), 8–19 (2005).
   PubMedGoogle Scholar
• Rudnick E, Khakoo Y, Antunes NL et al. Opsoclonus–myoclonus–ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies – a report from the Children’s Cancer Group Study. Med. Pediatr. Oncol.36(6), 612–622 (2001).
   PubMedGoogle Scholar
• Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso–myoclonus and neuroblastoma. Cancer37(2), 846–852 (1976).
   PubMed Web of Science ®Google Scholar
• Pranzatelli MR. The immunopharmacology of the opsoclonus–myoclonus syndrome. Clin. Neuropharmacol.19(1), 1–47 (1996).
   PubMed Web of Science ®Google Scholar
• Rostasy K, Wilken B, Baumann M et al. High dose pulsatile dexamethasone therapy in children with opsoclonus–myoclonus syndrome. Neuropediatrics37(5), 291–295 (2006).
   PubMed Web of Science ®Google Scholar
• Ertle F, Behnisch W, Al Mulla NA et al. Treatment of neuroblastoma-related opsoclonus–myoclonus–ataxia syndrome with high-dose dexamethasone pulses. Pediatr. Blood Cancer DOI 10.1002/pbc.21107 (2007) (Epub ahead of print).
   Google Scholar
• Pranzatelli MR, Tate ED, Travelstead AL et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J. Pediatr. Hematol. Oncol.28(9), 585–593 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong MB, Robertson PL, Castle VP. Delayed, recurrent opsoclonus–myoclonus syndrome responding to plasmapheresis. Pediatr. Neurol.33(5), 365–367 (2005).
   PubMedGoogle Scholar
• Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus–myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med. Pediatr. Oncol.28(4), 284–288 (1997).
   PubMed Web of Science ®Google Scholar
• Straube A, Leigh RJ, Bronstein A et al. EFNS task force – therapy of nystagmus and oscillopsia. Eur. J. Neurol.11(2), 83–89 (2004).
   PubMed Web of Science ®Google Scholar
• Caviness JN. Myoclonus. Mayo Clin. Proc.71(7), 679–688 (1996).
   PubMed Web of Science ®Google Scholar
• Ridley A, Kennard C, Scholtz CL et al. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain110(Pt 6), 1699–1709 (1987).
   PubMed Web of Science ®Google Scholar
• Kaneko CR. Effect of ibotenic acid lesions of the omnipause neurons on saccadic eye movements in rhesus macaques. J. Neurophysiol.75(6), 2229–2242 (1996).
   PubMed Web of Science ®Google Scholar
• Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J. Neurol. Sci.189(1–2), 71–81 (2001).
   PubMed Web of Science ®Google Scholar
• Ramat S, Leigh RJ, Zee DS, Optican LM. What clinical disorders tell us about the neural control of saccadic eye movements. Brain130(Pt 1), 10–35 (2007).
   PubMed Web of Science ®Google Scholar
• Blain PG, Nightingale S, Stoddart JC. Strychnine poisoning: abnormal eye movements. J. Toxicol.19(2), 215–217 (1982).
   PubMed Web of Science ®Google Scholar
• Tuchman RF, Alvarez LA, Kantrowitz AB et al. Opsoclonus–myoclonus syndrome: correlation of radiographic and pathological observations. Neuroradiology31(3), 250–252 (1989).
   PubMedGoogle Scholar
• Ziter FA, Bray PF, Cancilla PA. Neuropathologic findings in a patient with neuroblastoma and myoclonic encephalopathy. Arch. Neurol.36(1), 51 (1979).
   PubMedGoogle Scholar
• Hayward K, Jeremy RJ, Jenkins S et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus–myoclonus–ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J. Pediatr.139(4), 552–559 (2001).
   PubMed Web of Science ®Google Scholar
• Helmchen C, Rambold H, Sprenger A, Erdmann C, Binkofski F. Cerebellar activation in opsoclonus: an fMRI study. Neurology61(3), 412–415 (2003).
   PubMedGoogle Scholar
• Oguro K, Kobayashi J, Aiba H, Hojo H. Opsoclonus–myoclonus syndrome with abnormal single photon emission computed tomography imaging. Pediatr. Neurol.16(4), 334–336 (1997).
   PubMed Web of Science ®Google Scholar
• van Toorn R, Rabie H, Warwick JM. Opsoclonus–myoclonus in an HIV-infected child on antiretroviral therapy – possible immune reconstitution inflammatory syndrome. Eur. J. Paediatr. Neurol.9(6), 423–426 (2005).
   PubMed Web of Science ®Google Scholar
• Bellur SN. Opsoclonus: its clinical value. Neurology25(6), 502–507 (1975).
   PubMed Web of Science ®Google Scholar
• Kostulas VK, Link H, Lefvert AK. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch. Neurol.44(10), 1041–1044 (1987).
   PubMedGoogle Scholar
• Pranzatelli MR, Travelstead AL, Tate ED et al. B- and T-cell markers in opsoclonus–myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology62(9), 1526–1532 (2004).
   PubMed Web of Science ®Google Scholar
• Hero B, Berthold F. Neuroblastoma. Monatsschr. Kinderheilkund.150(6), 775–788 (2002).
   Google Scholar
• Martin RF, Beckwith JB. Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J. Pediatr. Surg.3(1), 161–164 (1968).
   PubMedGoogle Scholar
• Cooper R, Khakoo Y, Matthay KK et al. Opsoclonus–myoclonus–ataxia syndrome in neuroblastoma: histopathologic features – a report from the Children’s Cancer Group. Med. Pediatr. Oncol.36(6), 623–629 (2001).
   PubMedGoogle Scholar
• Gambini C, Conte M, Bernini G et al. Neuroblastic tumors associated with opsoclonus–myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch.442(6), 555–562 (2003).
   PubMed Web of Science ®Google Scholar
• Ollert MW, David K, Vollmert C et al. Mechanisms of in vivo anti-neuroblastoma activity of human natural IgM. Eur. J. Cancer33(12), 1942–1948 (1997).
   PubMedGoogle Scholar
• David K, Ehrhardt A, Ollert MW et al. Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid. Eur. J. Cancer33(12), 1937–1941 (1997).
   PubMedGoogle Scholar
• Korfei M, Fuhlhuber V, Schmidt-Woll T et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus–myoclonus-syndrome. J. Neuroimmunol.170(1–2), 150–157 (2005).
   PubMed Web of Science ®Google Scholar
• Cohn SL, Salwen H, Herst CV et al. Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus–myoclonus. Cancer62(4), 723–726 (1988).
   PubMed Web of Science ®Google Scholar
• Blaes F. Immunotherapeutic approaches to paraneoplastic neurological disorders. Expert Opin. Biol. Ther.2(4), 419–430 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher PG, Wechsler DS, Singer HS. Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr. Neurol.10(4), 309–312 (1994).
   PubMed Web of Science ®Google Scholar
• Graus F, Keime-Guibert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain124(Pt 6), 1138–1148 (2001).
   PubMed Web of Science ®Google Scholar
• Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/ sensory neuronopathy. Neurology41(11), 1757–1764 (1991).
   PubMed Web of Science ®Google Scholar
• Wang X, Tanaka Hall TM. Structural basis for recognition of AU-rich element RNA by the HuD protein. Nat. Struct. Biol.8(2), 141–145 (2001).
   PubMedGoogle Scholar
• Mobarak CD, Anderson KD, Morin M et al. The RNA-binding protein HuD is required for GAP-43 mRNA stability, GAP-43 gene expression, and PKC-dependent neurite outgrowth in PC12 cells. Mol. Biol. Cell11(9), 3191–3203 (2000).
   PubMed Web of Science ®Google Scholar
• Deschenes-Furry J, Mousavi K, Bolognani F et al. The RNA-binding protein HuD binds acetylcholinesterase mRNA in neurons and regulates its expression after axotomy. J. Neurosci.27(3), 665–675 (2007).
   PubMed Web of Science ®Google Scholar
• Antunes NL, Khakoo Y, Matthay KK et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J. Pediatr. Hematol. Oncol.22(4), 315–320 (2000).
   PubMed Web of Science ®Google Scholar
• Schafer KH, Klotz M, Mergner D et al. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J. Autoimmun.15(4), 479–484 (2000).
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tanaka M, Onodera O et al. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J. Neurol. Sci.127(2), 153–158 (1994).
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J. Neurosci.16(3), 1114–1122 (1996).
   PubMed Web of Science ®Google Scholar
• Jensen KB, Dredge BK, Stefani G et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron25(2), 359–371 (2000).
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Darnell RB. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol. Cell. Biol.17(6), 3194–3201 (1997).
   PubMedGoogle Scholar
• Bataller L, Rosenfeld MR, Graus F et al. Autoantigen diversity in the opsoclonus–myoclonus syndrome. Ann. Neurol.53(3), 347–353 (2003).
   PubMed Web of Science ®Google Scholar
• Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur. J. Biochem.227(1–2), 407–415 (1995).
   PubMedGoogle Scholar
• Nakajima K, Hamanoue M, Takemoto N et al. Plasminogen binds specifically to α-enolase on rat neuronal plasma membrane. J. Neurochem.63(6), 2048–2057 (1994).
   PubMed Web of Science ®Google Scholar
• Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S. α-enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol. Microbiol.40(6), 1273–1287 (2001).
   PubMed Web of Science ®Google Scholar
• Dot C, Guigay J, Adamus G. Anti-α-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung. Am. J. Ophthalmol.139(4), 746–747 (2005).
   PubMed Web of Science ®Google Scholar
• Fujii A, Yoneda M, Ito T et al. Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J. Neuroimmunol.162(1–2), 130–136 (2005).
   PubMedGoogle Scholar
• Linker K, Pautz A, Fechir M et al. Involvement of KSRP in the post-transcriptional regulation of human iNOS expression–complex interplay of KSRP with TTP and HuR. Nucleic Acids Res.33(15), 4813–4827 (2005).
   PubMedGoogle Scholar
• Gherzi R, Trabucchi M, Ponassi M et al. The RNA-binding protein KSRP promotes decay of β-catenin mRNA and is inactivated by PI3K–AKT signaling. PLoS Biol.5(1), e5 (2006).
   PubMed Web of Science ®Google Scholar
• Rehbein M, Wege K, Buck F et al. Molecular characterization of MARTA1, a protein interacting with the dendritic targeting element of MAP2 mRNAs. J. Neurochem.82(5), 1039–1046 (2002).
   PubMedGoogle Scholar
• Boeckers TM. The postsynaptic density. Cell. Tissue Res.326(2), 409–422 (2006).
   PubMed Web of Science ®Google Scholar
• Noetzel MJ, Cawley LP, James VL, Minard BJ, Agrawal HC. Anti-neurofilament protein antibodies in opsoclonus–myoclonus. J. Neuroimmunol.15(2), 137–145 (1987).
   PubMed Web of Science ®Google Scholar
• Stefansson K, Marton LS, Dieperink ME et al. Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals. Science228(4703), 1117–1119 (1985).
   PubMed Web of Science ®Google Scholar
• Braxton DB, Williams M, Kamali D et al. Specificity of human anti-neurofilament autoantibodies. J. Neuroimmunol.21(2–3), 193–203 (1989).
   PubMed Web of Science ®Google Scholar
• Salih AM, Nixon NB, Dawes PT, Mattey DL. Prevalence of antibodies to neurofilament polypeptides in patients with rheumatoid arthritis complicated by peripheral neuropathy. Clin. Exp. Rheumatol.16(6), 689–694 (1998).
   PubMedGoogle Scholar
• Connolly AM, Pestronk A, Mehta S, Pranzatelli MR 3rd, Noetzel MJ. Serum autoantibodies in childhood opsoclonus–myoclonus syndrome: an analysis of antigenic targets in neural tissues. J. Pediatr.130(6), 878–884 (1997).
   PubMed Web of Science ®Google Scholar
• Candler PM, Dale RC, Griffin S et al. Post-streptococcal opsoclonus–myoclonus syndrome associated with anti-neuroleukin antibodies. J. Neurol. Neurosurg. Psychiatr.77(4), 507–512 (2006).
   PubMed Web of Science ®Google Scholar
• Blaes F, Beeson D, Plested P, Lang B, Vincent A. IgG from “seronegative” myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann. Neurol.47(4), 504–510 (2000).
   PubMedGoogle Scholar
• Lily O, Palace J, Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain127(Pt 2), 269–279 (2004).
   PubMedGoogle Scholar
• Blaes F, Fuhlhuber V, Korfei M et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann. Neurol.58(2), 313–317 (2005).
   PubMed Web of Science ®Google Scholar
• Lee KH, Cho HJ, Kim HS et al. Activation of extracellular signal regulated kinase 1/2 in human dermal microvascular endothelial cells stimulated by anti-endothelial cell antibodies in sera of patients with Behcet’s disease. J. Dermatol. Sci.30(1), 63–72 (2002).
   PubMedGoogle Scholar
• Beck S, Fuhlhuber V, Krasenbrink I et al. IgG subclass distribution of autoantibodies in pediatric opsoclonus–myoclonus syndrome. J. Neuroimmunol.185(1–2), 145–149 (2007).
   PubMed Web of Science ®Google Scholar
• Ichiba N, Miyake Y, Sato K, Oda M, Kimoto H. Mumps-induced opsoclonus–myoclonus and ataxia. Pediatr. Neurol.4(4), 224–227 (1988).
   PubMed Web of Science ®Google Scholar
• Kuban KC, Ephros MA, Freeman RL, Laffell LB, Bresnan MJ. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann. Neurol.13(1), 69–71 (1983).
   PubMed Web of Science ®Google Scholar
• Delreux V, Kevers L, Callewaert A, Sindic C. Opsoclonus secondary to an Epstein–Barr virus infection. Arch. Neurol.46(5), 480–481 (1989).
   PubMedGoogle Scholar
• Khosla JS, Edelman MJ, Kennedy N, Reich SG. West Nile virus presenting as opsoclonus–myoclonus cerebellar ataxia. Neurology64(6), 1095 (2005).
   PubMed Web of Science ®Google Scholar
• Chemli J, Ketata S, Dalhoumi A et al. [Opsoclonus–myoclonus syndrome associated with Mycoplasma pneumoniae infection]. Arch. Pediatr.14(8), 1003–1006 (2007).
   PubMed Web of Science ®Google Scholar
• Wilfong AA, Parke JT, McCrary JA 3rd. Opsoclonus–myoclonus with Beckwith–Wiedemann syndrome and hepatoblastoma. Pediatr. Neurol.8(1), 77–79 (1992).
   PubMed Web of Science ®Google Scholar
• Anderson NE, Budde-Steffen C, Rosenblum MK et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine67(2), 100–109 (1988).
   PubMed Web of Science ®Google Scholar
• Averbuch-Heller L, Remler B. Opsoclonus. Semin. Neurol.16(1), 21–26 (1996).
   PubMed Web of Science ®Google Scholar
• Scharf D. Opsoclonus–myoclonus following the intranasal usage of cocaine. J. Neurol. Neurosurg. Psychiatr.52(12), 1447–1448 (1989).
   PubMed Web of Science ®Google Scholar
• Au WJ, Keltner JL. Opsoclonus with amitriptyline overdose. Ann. Neurol.6(1), 87 (1979).
   PubMed Web of Science ®Google Scholar
• Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA230(9), 1283–1287 (1974).
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron11(4), 657–672 (1993).
   PubMed Web of Science ®Google Scholar
• Kirsten A, Beck S, Fühlhuber V et al. New autoantibodies in paediatric opsoclonus-myoclonus syndrome. Ann. NY Acad. Sci.1110, 256–260 (2007).
   PubMed Web of Science ®Google Scholar
• Deconinck N, Scaillon M, Segers V, Groswasser JJ, Dan B. Opsoclonus–myoclonus associated with celiac disease. Pediatr. Neurol.34(4), 312–314 (2006).
   PubMedGoogle Scholar
• Blaes F, Jauss M, Kraus J et al. Adult paraneoplastic opsoclonus–myoclonus syndrome associated with antimitochondrial autoantibodies. J. Neurol. Neurosurg. Psychiatr.74(11), 1595–1596 (2003).
   PubMedGoogle Scholar